drugset / Trial / NCT06005740
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Phase 1
Recruiting
70 enrolled
TORL Biotherapeutics, LLC
Translational Research in Oncology · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Timeline
- Start
- 2023-12-04
- Primary completion
- 2025-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TORL-4-500 | Unknown | — | Intravenous |